Search Results

Your search matched 61 results

#1

Patient Advocacy at the Center of Patient-Centered Design | Blog

Representatives from small and big pharma, and those fighting both rare diseases and more prevalent ones, came together in San Diego recently for WIB-Southern California: The Growing Importance of Patient Advocacy in BioPharma.

#2

What Patient Advocacy Groups Want | Blog

And, turns out, it’s what patient advocacy groups want from pharma, too.

#3

How Patient Advocacy Connectivity Fuels Launch Success | Perspectives

Keri McDonough, our communications and advocacy relations strategist, lays out our top 10 recommendations for meaningful patient advocacy group engagement on the runway to launch and beyond.

#4

Patient Advocacy Transparency Act and the Growing Call for Disclosure | Blog

As anticipated, on June 6, 2018, Senator Claire McCaskill (D-Mo.) introduced the Patient Advocacy Transparency Act.

#5

August 2018: How Patient Advocacy Connectivity Fuels Launch Success | Newsletters

Keri McDonough, one of our patient advocacy specialists, provides ten recommendations on how to meaningfully engage with patient advocacy groups throughout the lifecycle of a product.

#6

SHARING THE MISSION TO CONQUER RARE DISEASES | Perspectives

At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases.

#7

BETTER TOGETHER: STRENGTHENING ADVOCACY-INDUSTRY PARTNERSHIPS | Perspectives

Since the fall of 2015, and against a backdrop of harsh media attention to pharmaceutical pricing, patient advocacy groups that form partnerships with pharma companies have received negative coverage in The New York Times, USA Today and other publications.

#8

Patient Advisory Boards Deliver Focused and Fruitful Insights, but Only When That’s Really the Goal | Perspectives

In this guest blog, Keri Mcdonough, Lead, Advocacy and Patient Relations at Syneos Health Communications shares her insight on how to assemble a patient advisory board that accurately and effectively represents the patient voice.

#9

Opening a New Era in Rare Disease Medicines | In The Media

Jeanine O'Kane and Marie Emms, senior executives at Syneos Health, address rare disease pricing and the ties between manufacturers, payers and patient advocacy groups.

#10

As Precision Medicine Grows, so Does the Importance of Clinical Trial Diversity | In The Media

Keri McDonough, Patient Advocacy Lead at Syneos Health Communications, was featured in MedCity News discussing how CROs can highlight the practical and socioeconomic barriers to greater trial diversity.

#11

Modern Activism in Healthcare: A Guide for Preventing Your Advocates from Becoming Activists | Perspectives

Our PR Group is just back from Strengthening Patient Advocacy Relations Conference where Meg Alexander, Head, Reputation & Risk Management & Chris Iafolla, Head, Digital & Social Strategy, presented “Worlds Colliding: When Patient Activism Meets Pharma’s Digital Channels".

#12

In Patient Advocacy,“Grassroots” Means Meeting People Face to Face | In The Media

Learn about why it's still important to consider a human approach in healthcare communications from Jeanine O'Kane, President, Public Relations Group at inVentiv Health Communications.

#13

THE NEW PARTNERSHIP PARADIGM: WHAT PATIENT ADVOCATES SEEK FROM PHARMACEUTICAL PARTNERS | Perspectives

Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies form with groups representing patients and families.

#14

Top Patient and Advocate Quotes for Pharma from eyeforpharma ‘18 | Blog

Live from EFP ‘18: This afternoon, a panel of 5 patients, advocates and pharma-patient connectors engaged in a discussion titled, “Where is the trust?

#15

A new approach to fighting drug shortages | Blog

Shortages of critical cancer-fighting drugs have impacted 83% of U.S. oncologists in the past six months.* Around the world, doctors are negotiating availability, access and funding for the infusions they most want to prescribe.

#16

Patient-Finding Approaches for Rare Disease | Blog

Mark Baglin, Vice President of Global Marketing at Alnylam Pharmaceuticals, works in ultra ultra rare diseases, like Hereditary ATTR Amyloidosis.

#17

Betting Big on Cancer.com | Blog

This month, Janssen launched Cancer.com, aiming to create an online destination for all things oncology.

#18

Clinical Educators: Positive Impact on Patient Experiences | Perspectives

Clinical educators can help empower the patient to make their own informed healthcare choices.

#19

Chandler Chicco Agency | Agency

Global PR agency pioneering health communications programs that engage key stakeholders throughout the product lifecycle.

#20

What Do You Get When You Combine Scientists and Patients? | Blog

This summer, students in California Institute for Regenerative Medicine’s Bridges to Stem Cell Research and Therapy program at California State University (CSU) San Marcos had new lab partners: families impacted by rare diseases.

#21

AN ADVOCACY RX FOR PROGRESS IN MENTAL HEALTH | Perspectives

As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled public health crisis.

#22

Spring Pharma Forecast: Partly Cloudy with Gusts of Transparency | Blog

TWTW team spent this weekend doing some spring cleaning in the hopes that it would bring us East Coasters some, well, spring…Fingers crossed that a little wishful thinking and the removal of some pretty major dust bunnies will get the warm weather vibes coming our way.

#23

Reputation & Risk Management | Shared-accelerator

Reputation & Risk Management

#24

The Hero’s Journey Art Project: Using Social Media to Raise Awareness of Clinical Research – A Year Later Account | Blog

These patients represent the foundation of getting new and better treatments FDA-approved and in the hands of the patients that need them.

#25

Fake News Invades Healthcare | Blog

The “fake news” phenomenon is more than just a problem for politics.

#26

Advancing the Patient Voice in Clinical Trials | Blog

Recently, the FDA issued Collecting Comprehensive and Representative Input, the first of four patient-focused drug development (PFDD) guidance documents.

#27

The Rep Evolution | Blog

Recently, one of our clients asked the GSW innovation team if there was some way to flip the typical rep ad board meeting and turn it into something more engaging… more productive… more (saw this one coming) innovative.

#28

Insulin Prices Halved by Eli Lilly | Blog

Responding to rampant criticism of rising drug prices, pharma giant Eli Lilly will begin selling an authorized generic of its preeminent insulin therapy, Humalog, at half-price.

#29

2017 Lions Health: All the Highlights from Cannes | Blog

Live From Lions Health: This is the fourth year Cannes has hosted a special conference and award show focused on health and life-changing creativity.

#30

The Launch of a Non-Traditional Unbranded Multi-Channel Campaign in Pharma | Blog

What comes to mind when you think of a successful unbranded disease awareness campaign?